Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Above Fifty Day Moving Average – Should You Sell?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)’s share price passed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $3.39 and traded as high as $3.55. Oramed Pharmaceuticals shares last traded at $3.44, with a volume of 61,539 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Oramed Pharmaceuticals in a report on Friday, March 27th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has an average rating of “Hold”.

Oramed Pharmaceuticals Stock Down 1.1%

The stock has a market capitalization of $140.77 million, a P/E ratio of 2.34 and a beta of 1.26. The business has a fifty day moving average price of $3.39 and a 200-day moving average price of $2.98.

Oramed Pharmaceuticals (NASDAQ:ORMP) last announced its quarterly earnings results on Friday, March 27th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. On average, equities analysts expect that Oramed Pharmaceuticals Inc. will post -0.03 earnings per share for the current fiscal year.

Institutional Trading of Oramed Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Redwood Family Wealth LLC purchased a new stake in Oramed Pharmaceuticals in the fourth quarter worth about $66,000. SB Capital Management Inc purchased a new stake in shares of Oramed Pharmaceuticals during the fourth quarter worth about $5,415,000. XTX Topco Ltd grew its position in shares of Oramed Pharmaceuticals by 59.9% during the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 14,297 shares in the last quarter. Quadrature Capital Ltd purchased a new stake in shares of Oramed Pharmaceuticals during the fourth quarter worth about $119,000. Finally, Squarepoint Ops LLC grew its position in shares of Oramed Pharmaceuticals by 95.1% during the fourth quarter. Squarepoint Ops LLC now owns 58,272 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 28,406 shares in the last quarter. Hedge funds and other institutional investors own 12.73% of the company’s stock.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.